COMMUNIQUÉS West-GlobeNewswire
 
      -   
  GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies23/10/2025
-   
  Gelteq Announces Commencement of Preclinical Trial Targeting Oil Soluble Drug Market with Novel Delivery Platform23/10/2025
-   
  Visory Health Partners with Albertsons Companies to Expand Access to Affordable Prescriptions Nationwide23/10/2025
-   
  Synfini Selected for SLAS 2026 Innovation AveNEW Showcase23/10/2025
-   
  Solana Company (NASDAQ: HSDT) Strengthens Treasury Strategy with Helius, Anchorage Digital and Twinstake Staking Services23/10/2025
-   
  Exagen Announces Acceptance of Six Abstracts at 2025 American College of Rheumatology Convergence23/10/2025
-   
  BeautyHealth to Report Third Quarter 2025 Financial Results on November 6, 202523/10/2025
-   
  IMUNON to Present New Translational Data from Phase 2 OVATION 2 Study of IMNN-001 at SITC 40th Annual Meeting23/10/2025
-   
  PCI Biotech update23/10/2025
-   
  Abalos Therapeutics Doses First Patient in Phase 1 Study Evaluating ABX-001 for the Treatment of Solid Tumors23/10/2025
-   
  Hydreight Reports Corporate Update and Ranks #25 on Deloitte’s 2025 Technology Fast 50™23/10/2025
-   
  Silver Creek Pharmaceuticals Announces Positive Phase 2 Results for Scp776 in Acute Ischemic Stroke23/10/2025
-   
  'The World’s Greatest Health Van' Travels to Ottawa: 150,000 Canadians Call for The Charter of Health Freedom23/10/2025
-   
  Pharvaris to Present Clinical Data at the ACAAI 2025 Annual Scientific Meeting23/10/2025
-   
  TLX250-CDx (Zircaix) Included in Leading International Guidelines for Renal Imaging23/10/2025
-   
  Tango Therapeutics Reports Positive Data from Ongoing Phase 1/2 Study with Vopimetostat (TNG462) in Patients with MTAP-deleted Cancers23/10/2025
-   
  Amicus Therapeutics to Announce Third Quarter 2025 Financial Results on November 4, 202523/10/2025
-   
  Ligand to Report Third Quarter 2025 Financial Results on November 6, 202523/10/2025
-   
  INmune Bio Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on Thursday, October 30, 202523/10/2025
Pages